In contrast, NHE1 is linked to promoting motility in ErbB2-positive breast cancer cells, stimulating the epithelial-to-mesenchymal transition (EMT) and contributing to chemotherapy resistance [65,66,70,71,72]. Here, SLC9A1 is linked to breast cancer.